34 12-Year Review of Surgical Outcomes in Implant-Based Reconstructions With Modification and Optimization of Mastectomy Flap Geometry and Soft Tissue Quality: a Retrospective Review of 900 Implant-Based Breast Reconstructions

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement40th Annual Miami Breast Cancer Conference® - Abstracts
Volume 37
Issue suppl 4
Pages: 40-41


Background

Implant-based reconstructions are the most common form of postmastectomy reconstruction. Mastectomy flap necrosis is a dreaded complication leading to poor outcomes and patient dissatisfaction. The correct surgical technique when performing mastectomy flap elevation is a key factor in flap viability. Mastectomy flaps are random dermal flaps; therefore, in addition to anatomically correct flap dissection and elevation, a favorable flap length-to-base ratio is of great importance. Traditional mastectomy incisions used a simple elliptical excision of the central breast skin, including the nipple-areolar complex, and resulted in broad-based and short mastectomy flaps or random dermal flaps; therefore, in addition to anatomically correct flap dissection and elevation, a favorable flap length-to-base ratio is of great importance. Traditional mastectomy incisions used a simple elliptical excision of the central breast skin, including the nipple-areolar complex, and resulted in broad-based and short mastectomy flaps. Over the last 20 years, skin-sparing mastectomies, as well as complete skin-sparing nipple-sparing mastectomies with immediate reconstruction, have gained popularity. Preserving all or most of the skin envelope resulted in much longer mastectomy flaps. Additionally, the mastectomy flaps now also include the central breast skin with its extreme paucity of subcutaneous fat as well as the nipple-areolar complex with a complete absence of subcutaneous fat, and a merge of the ductal parenchyma with the dermal plane. These long and central breast areas, very thin flaps, were now used to cover the prosthetic devices. This resulted in double-digit reports of mastectomy skin necrosis, as well as increased rates of infections, seromas, implant loss, reoperations, and poor patient outcomes. We describe a simple modification of the mastectomy skin envelope, which allows for the recruitment of thicker chest wall skin over the implants, a shortening of overall mastectomy flap length, and a doubling up of soft tissue in the lower implant pocket by using a de-epithelialized dermal flap. Nipple-sparing procedures are achieved by grafting the nipple-areolar complex as a full-thickness graft onto the correct anatomical position on the mastectomy.

Methods

A retrospective chart review was performed of all patients who underwent wise pattern modification of their mastectomy flaps and implant-based reconstructions from 2010 to 2022 by the first author. Demographic, clinical, and operative data were recorded. Outcomes were assessed by evaluation of surgical complication rates, including mastectomy flap necrosis, seroma, hematoma infection, capsular contracture, and implant loss.

Results

Nine-hundred-and-four wise pattern mastectomies were performed in 509 patients with a mean age of 52.5 years and a mean body mass index of 28.8. In the cohort, 28 (3.3%) patients were active smokers, 30 were diabetic (5%), and 135 (14.5%) mastectomies underwent chest wall radiation. Complication rates compared favorably to published data of non–wise pattern mastectomies with implant-based reconstructions. We encountered major mastectomy flap necrosis in 15 breasts (1.6%), capsular contracture in 57 patients (6.3%), major infection in 21 breasts (2.3%), implant loss in 26 breasts (2.8%), seroma in 3 breasts (0.3%), and hematoma in 5 breasts (0.5%) of reconstructed breasts. Major infections were the leading cause of temporary or permanent implant loss. All capsular contractures occurred in radiated patients.

Conclusions

The results of this large cohort study of mastectomy reconstructions over 12 years with a modified mastectomy skin envelope to optimize mastectomy flap viability in immediate implant-based reconstructions show that overall complication rates are reduced compared to data published in the literature. While clinical results are encouraging, further anatomical studies on the vasculature and soft tissue thickness of the modified versus traditional flaps are needed.

AFFILIATIONS:

Anke Ott Young,1,2,3 Christine Hody,1,3 Melanie Lynch,1 Amit Elazar,3 Sravya Chilukuri,3 Lillian Huang,3 Rheda Young,4 Tomasso Addona,2 Mary Pronovost5

1Yale New Haven Health, New Haven, CT.

2New York Plastic Surgery Group, New York, NY.

3Mount Sinai South Nassau, Oceanside, NY.

4Schule Schloss Salem, Salem, Germany.

5Lewis Katz School of Medicine, Philadelphia, PA.

Articles in this issue

1 Elacestrant Versus Fulvestrant or Aromatase Inhibitor in a Phase 3 Trial Evaluating Elacestrant, an Oral Selective Estrogen Receptor Degrader Versus Standard-of- Care Endocrine Monotherapy for ER+/HER2– Advanced/Metastatic Breast Cancer
1 Elacestrant Versus Fulvestrant or Aromatase Inhibitor in a Phase 3 Trial Evaluating Elacestrant, an Oral Selective Estrogen Receptor Degrader Versus Standard-of- Care Endocrine Monotherapy for ER+/HER2– Advanced/Metastatic Breast Cancer
2 Molecular Characterization of HER2-Low Patients Identifies Basal-Enriched Subset With Poor Clinical Outcomes in Real-world Data
2 Molecular Characterization of HER2-Low Patients Identifies Basal-Enriched Subset With Poor Clinical Outcomes in Real-world Data
3 Real-world Outcomes of Sacituzumab Govitecan in Metastatic Breast Cancer Patients: A Single Institution Experience
3 Real-world Outcomes of Sacituzumab Govitecan in Metastatic Breast Cancer Patients: A Single Institution Experience
4 Datopotamab Deruxtecan (Dato-DXd) + Durvalumab (D) as First-Line (1L) Treatment for Unresectable Locally Advanced/ Metastatic Triple-Negative Breast Cancer (a/mTNBC): Updated Results From BEGONIA, a Phase 1b/2 Study
4 Datopotamab Deruxtecan (Dato-DXd) + Durvalumab (D) as First-Line (1L) Treatment for Unresectable Locally Advanced/ Metastatic Triple-Negative Breast Cancer (a/mTNBC): Updated Results From BEGONIA, a Phase 1b/2 Study
5 Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib Combinations as First- Line Treatment for Advanced or Metastatic Breast Cancer in Realworld Settings in Argentina and Colombia: Results from the IRIS Study
5 Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib Combinations as First- Line Treatment for Advanced or Metastatic Breast Cancer in Realworld Settings in Argentina and Colombia: Results from the IRIS Study
7 EMERALD Phase 3 Trial of Elacestrant Versus Standard-of- Care Endocrine Therapy in Patients With ER+/HER2– Metastatic Breast Cancer: Updated Results by Duration of Prior CDK4/6i in Metastatic Setting
7 EMERALD Phase 3 Trial of Elacestrant Versus Standard-of- Care Endocrine Therapy in Patients With ER+/HER2– Metastatic Breast Cancer: Updated Results by Duration of Prior CDK4/6i in Metastatic Setting
8 Datopotamab Deruxtecan (Dato-DXd) in Advanced Triple- Negative Breast Cancer (TNBC): Updated Results From the Phase 1 TROPION-PanTumor01 Study
8 Datopotamab Deruxtecan (Dato-DXd) in Advanced Triple- Negative Breast Cancer (TNBC): Updated Results From the Phase 1 TROPION-PanTumor01 Study
9 Phase 1 TROPION-PanTumor01 Study Evaluating Datopotamab Deruxtecan (Dato-DXd) in Unresectable or Metastatic Hormone Receptor–Positive/ Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer
9 Phase 1 TROPION-PanTumor01 Study Evaluating Datopotamab Deruxtecan (Dato-DXd) in Unresectable or Metastatic Hormone Receptor–Positive/ Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer
11 Real-world Treatment Patterns and Effectiveness of Palbociclib Plus an Aromatase Inhibitor in Patients With Metastatic Breast Cancer Aged 75 Years or Above
11 Real-world Treatment Patterns and Effectiveness of Palbociclib Plus an Aromatase Inhibitor in Patients With Metastatic Breast Cancer Aged 75 Years or Above
12 TIP HARMONIA SOLTI-2101/ AFT-58: A Head-to-Head Phase III Study Comparing Ribociclib (RIB) and Palbociclib (PAL) in Patients (pts) With Hormone Receptor– Positive/HER2-Negative/HER2- Enriched (HR+/HER2−/HER2-E) Advanced Breast Cancer (ABC)
12 TIP HARMONIA SOLTI-2101/ AFT-58: A Head-to-Head Phase III Study Comparing Ribociclib (RIB) and Palbociclib (PAL) in Patients (pts) With Hormone Receptor– Positive/HER2-Negative/HER2- Enriched (HR+/HER2−/HER2-E) Advanced Breast Cancer (ABC)
13 Improved Sensitivity in Identification of ER- and HER2- Expressing Metastatic Breast Cancers With a Combination of Cell & Cell-Free Liquid Biopsy Analysis
13 Improved Sensitivity in Identification of ER- and HER2- Expressing Metastatic Breast Cancers With a Combination of Cell & Cell-Free Liquid Biopsy Analysis
15 Updated Expert Consensus Recommendations for Managing Hyperglycemia and Rash in Patients With PIK3CA-Mutated, Hormone Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2–Negative (HER2–) Advanced Breast Cancer Treated With Alpelisib
15 Updated Expert Consensus Recommendations for Managing Hyperglycemia and Rash in Patients With PIK3CA-Mutated, Hormone Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2–Negative (HER2–) Advanced Breast Cancer Treated With Alpelisib
16 Primary Results From the Randomized Phase II RIGHT Choice Trial of Premenopausal Patients With Aggressive HR+/HER2− Advanced Breast Cancer Treated With Ribociclib + Endocrine Therapy vs Physician’s Choice Combination Chemotherapy
16 Primary Results From the Randomized Phase II RIGHT Choice Trial of Premenopausal Patients With Aggressive HR+/HER2− Advanced Breast Cancer Treated With Ribociclib + Endocrine Therapy vs Physician’s Choice Combination Chemotherapy
17 A Clinical Systematic Literature Review of Treatments Among Patients With Advanced/ Metastatic HER2+ Breast Cancer
17 A Clinical Systematic Literature Review of Treatments Among Patients With Advanced/ Metastatic HER2+ Breast Cancer
20 TIP ELONA: An Open-Label, Phase 1b-2 Study of Elacestrant, in Combination With Onapristone in Patients With Estrogen Receptor– Positive, Progesterone Receptor– Positive, HER2-Negative Advanced or Metastatic Breast Cancer
20 TIP ELONA: An Open-Label, Phase 1b-2 Study of Elacestrant, in Combination With Onapristone in Patients With Estrogen Receptor– Positive, Progesterone Receptor– Positive, HER2-Negative Advanced or Metastatic Breast Cancer
Related Content